'''抗血清'''（Antiserum）是含有單株或[[多株B細胞反應|多株]][[抗體|抗體]]的人類或非人類[[血清|血清]]；注到生物體後，可以產生[[被動免疫|被動免疫]]。例如目前已知唯一有效的[[埃博拉出血热|埃博拉出血热]]治療法，就是從倖存者中取得抗血清（恢復期血清，convalescent serum），再將抗血清輸到其他人體內（但成功率很低）<ref>{{cite journal|last1=Mupapa|first1=K|last2=Massamba|first2=M|last3=Kibadi|first3=K|last4=Kuvula|first4=K|last5=Bwaka|first5=A|last6=Kipasa|first6=M|last7=Colebunders|first7=R|last8=Muyembe-Tamfum|first8=JJ|title=Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients (suppl 1)|journal=The Journal of Infectious Diseases|date=1999|issue=Volume 179|pages=S18-S23|doi=10.1086/514298|url=http://jid.oxfordjournals.org/content/179/Supplement_1/S18.full?sid=b139b993-6946-4bf7-a999-9fc837193bda|accessdate=6 August 2014|pmid=9988160|volume=179 Suppl 1|archive-date=2020-05-08|archive-url=https://web.archive.org/web/20200508073729/https://academic.oup.com/jid/issue/179/suppl_1?sid=b139b993-6946-4bf7-a999-9fc837193bda|dead-url=no}}</ref>。

抗血清常用在診斷[[病毒学|病毒学]]的實驗室中。抗血清若用在人類身上，常當作{{le|抗毒素|antitoxin}}或是治療{{le|蛇毒|envenomation}}的[[抗蛇毒血清|抗蛇毒血清]]。

==历史==

==现代应用==

在[[2019冠状病毒病|2019冠状病毒病]]的早期阶段，还没有找到可靠的治疗方案。对此，恢复期血清被认为是一种可能的，至少在严重的情况下已经被用作一种治疗方案。<ref>{{Cite web |url=https://ec.europa.eu/health/blood_tissues_organs/covid-19_en |title=存档副本 |access-date=2020-08-24 |archive-date=2021-03-17 |archive-url=https://web.archive.org/web/20210317131003/https://ec.europa.eu/health/blood_tissues_organs/covid-19_en |dead-url=no }}</ref> <ref>{{Cite web |url=https://www.pei.de/EN/newsroom/press-releases/year/2020/07-pei-approves-first-covid-19-therapy-study-with-convalescent-plasma.html |title=存档副本 |access-date=2020-08-24 |archive-date=2021-01-07 |archive-url=https://web.archive.org/web/20210107081212/https://www.pei.de/EN/newsroom/press-releases/year/2020/07-pei-approves-first-covid-19-therapy-study-with-convalescent-plasma.html |dead-url=no }}</ref><ref>{{Cite web |url=https://www.uscovidplasma.org/ |title=存档副本 |access-date=2020-08-24 |archive-date=2021-03-23 |archive-url=https://web.archive.org/web/20210323022535/https://www.uscovidplasma.org/ |dead-url=no }}</ref>

==運作原理==

<!--{{ course assignment | course = Education Program:Louisiana State University/ENGL 2000: English Composition (Spring 2015) | term = 2015 Q1 }}-->
抗血清中的抗體會和[[抗原|抗原]]或是傳染媒介結合<ref>de Andrade, Fábio Goulart, et al. "The Production And Characterization Of Anti-Bothropic And Anti-Crotalic Igy Antibodies In Laying Hens: A Long Term Experiment." Toxicon 66.(2013): 18-24. Academic Search Complete. Web. 12 Feb. 2015.</ref>。[[免疫系统|免疫系统]]會識別和抗體結合的外來物質，觸發更强烈的[[免疫反應|免疫反應]]。抗血清多半會用在致病原的強度界於一定程度之間的情形：抗血清可以躲避尚未活化的免疫系統，但只要免疫系統活化，致病原就無法躲避。因此是否有抗體要看一開始的「幸運倖存者」其免疫系統是否有辦法產生抗體，或是看是否有攜帶致病體但不會受其症狀影響的「宿主物種」<ref>Mortimer, Nathan T., et al. "Parasitoid Wasp Venom SERCA Regulates Drosophila Calcium Levels And Inhibits Cellular Immunity." Proceedings Of The National Academy Of Sciences Of The United States Of America 110.23 (n.d.): 9427-9432. Biological Abstracts 1969 - Present. Web. 12 Feb. 2015.</ref>。後續的抗血清可以從初始的抗血清提供者產生，或是從曾被感染，但之後因為抗血清而治癒的動物器官來產生。像稀釋的蛇毒常常是蛇本身的抗血清，在蛇咬到自己時可以產生被動免疫<ref>O'Leary, M.A., K. Maduwage, and G.K. Isbister. "Use Of Immunoturbidimetry To Detect Venom–Antivenom Binding Using Snake Venoms." Journal Of Pharmacological & Toxicological Methods 67.3 (2013): 177-181. Academic Search Complete. Web. 12 Feb. 2015.</ref><ref>Vogel, Carl-Wilhelm, Paul W. Finnegan, and David C. Fritzinger. "Humanized Cobra Venom Factor: Structure, Activity, And Therapeutic Efficacy In Preclinical Disease Models." Molecular Immunology 61.2 (2014): 191-203. Academic Search Complete. Web. 12 Feb. 2015.</ref>。

==參考資料==
{{reflist}}

==外部連結==
* {{MeshName|Antisera}}

{{Immune sera and immunoglobulins}}

{{Authority control}}
[[Category:血液|Category:血液]]